NIHR Experimental Cancer Medicine Centre (ECMC)

We are part of the Experimental Cancer Medicine Centre (ECMC) Network, made of up 18 adult and nine paediatric centres across the UK, each with their own unique area of expertise. As one of these centres, we and Wessex's patients benefit from the extensive expertise in cancer research and funding the network brings.

UK wide network

The ECMC Network supports the delivery of early phase cancer studies to accelerate and personalise new treatments for patients. The network fosters collaboration, bringing together clinicians and scientists from across the UK to deliver world class research.

All ECMC centres are linked with hospital-university partnerships with strengths in cancer research. These teams are committed to fast development of medicines from lab to clinic, to ensure the best possible survivorship and quality of life for cancer patients in the UK and world wide  .

Funding from the ECMC supports staff members within these centres, with flexibility  to allocate it strategically across a number of research themes.

Southampton - harnessing the body's own defences

The WISH lab draws on Southampton's leadership in immunotherapy research to develop new treatments for solid and haematological cancers. It does so by hosting the Quality Assurance (QA) and Translational scientists of the Southampton ECMC, and working closely with the Southampton clinical trials unit (CTU), the Centre for Drug Development (CDD) at Cancer Research UK( CRUK) and other trial sponsors. We provide the specialist laboratory, administrative and clinical delivery support needed to deliver early phase studies quickly and effectively.

Southampton is a national centre of excellence in lymphoma and melanoma care research, with specialist clinical services for other major cancer types. It has medical imaging, cellular therapy and radiopharmacy facilities and hosts a fully Human Tissue Association (HTA) accredited tissue bank. 

Find out more about ECMC Network here.